| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -395,064 | -231,923 |
| Depreciation and amortization | 8,782 | 5,784 |
| Amortization of premiums on investments, net | -7,925 | -6,610 |
| Noncash lease expense | 3,655 | 2,358 |
| Change in fair value of equity investments | -4,335 | -3,000 |
| Change in estimated fair value of contingent consideration | 11,570 | 11,010 |
| Payment of contingent consideration in excess of acquisition date fair value | -17,140 | -17,140 |
| Stock-based compensation | 37,866 | 26,510 |
| In-process research and development impairment | 0 | 0 |
| Long-lived assets impairment and disposal loss | 399 | 399 |
| Other non-cash items, net | 40 | 59 |
| Prepaid expenses and other current assets | -10,152 | -5,937 |
| Other assets | 3,924 | 1,132 |
| Accounts payable | 2,042 | 7,444 |
| Accrued liabilities and other long-term liabilities | -19,613 | -5,458 |
| Operating lease liabilities | -5,045 | -3,253 |
| Deferred revenue | -3,215 | -2,540 |
| Net cash used in operating activities | -365,905 | -198,335 |
| Proceeds from sale of equipment | 363 | 326 |
| Purchases of long-lived assets | 4,484 | 4,167 |
| Purchases of investments | 630,512 | 366,065 |
| Maturities and sales of investments | 858,353 | 553,180 |
| Net cash provided by investing activities | 223,720 | 183,274 |
| Proceeds from exercise of stock options | 1,348 | 1,247 |
| Issuance of common stock under espp | 1,757 | 1,757 |
| Other financing activities | -359 | -360 |
| Net cash provided by financing activities | 2,746 | 2,644 |
| Net (decrease) increase in cash, cash equivalents and restricted cash and cash equivalents | -139,439 | -12,417 |
| Cash and cash equivalents at end of period | 179,256 | - |
Vir Biotechnology, Inc. (VIR)
Vir Biotechnology, Inc. (VIR)